Federal Register / Vol. 75, No. 38 / Friday, February 26, 2010 / Notices 8981 

II. Meeting Format 

This meeting is open to the public. 

The Committee will hear oral 

presentations from the public for 

approximately 45 minutes. The 

Committee may limit the number and 

duration of oral presentations to the 

time available. Your comments should 

focus on issues specific to the list of 

topics that we have proposed to the 

Committee. The list of research topics to 

be discussed at the meeting will be 

available on the following Web site 

prior to the meeting: http:// 

www.cms.hhs.gov/mcd/ 

index_list.asp?list_type=mcac. We 

require that you declare at the meeting 

whether you have any financial 

involvement with manufacturers (or 

their competitors) of any items or 

services being discussed. 

The Committee will deliberate openly 

on the topics under consideration. 

Interested persons may observe the 

deliberations, but the Committee will 

not hear further comments during this 

time except at the request of the 

chairperson. The Committee will also 

allow a 15-minute unscheduled open 

public session for any attendee to 

address issues specific to the topics 

under consideration. At the conclusion 

of the day, the members will vote and 

the Committee will make its 

recommendation(s) to CMS. 

III. Registration Instructions 

CMS’s Coverage and Analysis Group 

is coordinating meeting registration. 

While there is no registration fee, 

individuals must register to attend. You 

may register by contacting the person 

listed in the FOR FURTHER INFORMATION

CONTACT section of this notice by the 

deadline listed in the DATES section of 

this notice. Please provide your full 

name (as it appears on your state-issued 

driver’s license), address, organization, 

telephone, fax number(s), and e-mail 

address. You will receive a registration 

confirmation with instructions for your 

arrival at the CMS complex or you will 

be notified the seating capacity has been 

reached. 

IV. Security, Building, and Parking 

Guidelines 

This meeting will be held in a Federal 

government building; therefore, Federal 

security measures are applicable. We 

recommend that confirmed registrants 

arrive reasonably early, but no earlier 

than 45 minutes prior to the start of the 

meeting, to allow additional time to 

clear security. Security measures 

include the following: 

• Presentation of government-issued 

photographic identification to the 

Federal Protective Service or Guard 

Service personnel. 

• Inspection of vehicle’s interior and 

exterior (this includes engine and trunk 

inspection) at the entrance to the 

grounds. Parking permits and 

instructions will be issued after the 

vehicle inspection. 

• Inspection, via metal detector or 

other applicable means of all persons 

entering the building. We note that all 

items brought into CMS, whether 

personal or for the purpose of 

presentation or to support a 

presentation, are subject to inspection. 

We cannot assume responsibility for 

coordinating the receipt, transfer, 

transport, storage, set-up, safety, or 

timely arrival of any personal 

belongings or items used for 

presentation or to support a 

presentation. 

Note: Individuals who are not registered in 

advance will not be permitted to enter the 

building and will be unable to attend the 

meeting. The public may not enter the 

building earlier than 45 minutes prior to the 

convening of the meeting. All visitors must 

be escorted in areas other than the lower and 

first floor levels in the Central Building. 

Authority: 5 U.S.C. App. 2, section 10(a). 

(Catalog of Federal Domestic Assistance 

Program No. 93.773, Medicare—Hospital 

Insurance; and Program No. 93.774, 

Medicare—Supplementary Medical 

Insurance Program) 

Dated: February 4, 2010. 

Barry M. Straube, 

Chief Medical Officer and Director, Office 

of Clinical Standards and Quality, Centers 

for Medicare & Medicaid Services. 

[FR Doc. 2010–3724 Filed 2–25–10; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Treatment of Glaucoma by 

Administration of Adenosine A3 

Antagonists 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

part 404.7(a)(1)(i), that the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the inventions 

embodied in U.S. Provisional Patent 

Application 60/010,737, entitled 

‘‘Dihydropyridine, pyridine-, 

benzopyran one-, and 

triazoloquinazoline derivatives, their 

preparation and use as adenosine 

receptor antagonists,’’ filed January 29, 

1996 [HHS Ref. No. E–225–1995/0–US– 

1], U.S. Provisional Patent Application 

60/021,191, entitled ‘‘Dihydropyridine, 

pyridine-, benzopyran one-, and 

triazoloquinazoline derivatives, their 

preparation and use as adenosine 

receptor antagonists,’’ filed July 3, 1996 

[HHS Ref. No. E–225–1995/1–US–1], 

PCT Application PCT/US97/01252, 

entitled ‘‘Dihydropyridine, pyridine-, 

benzopyran one-, and 

triazoloquinazoline derivatives, their 

preparation and use as adenosine 

receptor antagonists,’’ filed January 29, 

1997 [HHS Ref. No. E–225–1995/2– 

PCT–1], U.S. Patent 6,066,642, entitled 

‘‘Dihydropyridine, pyridine-, 

benzopyran one-, and 

triazoloquinazoline derivatives, their 

preparation and use as adenosine 

receptor antagonists,’’ issued May 23, 

2000 [HHS Ref. No. E–225–1995/2–US– 

08], Australian Patent 709190, issued 

December 9, 1999 [HHS Ref. No. E–225– 

1995/2–AU–04], European Patent 

Application No. 97905627.2, filed 

January 29, 1997 [HHS Ref. No. E–225– 

1995/2–EP–05], Hong Kong Application 

No. 99102653.6, filed January 29, 1997 

[HHS Ref. No. E–225–1995/2–HK–06], 

Japanese Patent Application No. 

527065/1997, filed January 29, 1997 

[HHS Ref. No. E–225–1995/2–JP–07], 

Australian Patent 755525, issued March 

27, 2003 [HHS Ref. No. E–225–1995/2– 

AU–02], and Canadian Patent 2244774, 

issued October 17, 2006 [HHS Ref. No. 

E–225–1995/2–CA–03], U.S. Provisional 

Patent Application 60/092,292, entitled 

‘‘A3 Adenosine Receptor Antagonists,’’ 

filed July 10, 1998 [HHS Ref. No. E– 

096–1998/0–US–1], PCT Application 

PCT/US99/15562, entitled’’A3 

Adenosine Receptor Antagonists,’’ filed 

July 2, 1999 [HHS Ref. No. E–096–1998/ 

0–PCT–2], U.S. Patent 6,376,521, 

entitled ‘‘A3 Adenosine Receptor 

Antagonists,’’ issued April 23, 2003, 

[HHS Ref. No. E–096–1998/0–US–04], 

and Canadian Patent Application No. 

2336967, filed July 2, 1999 [HHS Ref. 

No. E–096–1998/0–CA–03], U.S. 

Provisional Patent Application 61/ 

085,588, entitled ‘‘Truncated 

Methanacarba Adenosine Derivatives as 

A3 Antagonists,’’ filed August 1, 2008 

[HHS Ref. No. E–285–2008/0–US–1], 

PCT Application PCT/US2009/52439, 

entitled ‘‘Truncated Methanacarba 

Adenosine Derivatives as A3 

Antagonists,’’ filed July 31, 2009 [HHS 

Ref. No. E–285–2008/0–PCT–2], and 

Korean International Application No. 

PCT/KR2007/001131, entitled 


sroberts on DSKD5P82C1PROD with NOTICES
8982 Federal Register / Vol. 75, No. 38 / Friday, February 26, 2010 / Notices 

‘‘Adenosine derivatives, method of 

synthesis thereof, and the 

pharmaceutical compositions for the 

prevention and treatment of the 

inflammatory diseases containing the 

same as an active ingredient,’’ filed 

March 7, 2007, [HHS Ref. No. E–109– 

2006/0–PCT–01] to Acorn Biomedical, 

Inc., having an office in at 612 SE. 5th 

Avenue, Suite #3, Fort Lauderdale, FL 

33301 U.S.A. The patent rights in these 

inventions have been assigned to the 

United States of America. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use may be limited to the use 

of adenosine A3 antagonists for 

treatment of glaucoma and intraocular 

pressure. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before March 

29, 2010 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated exclusive license should 

be directed to: Steven Standley, Ph.D., 

Licensing and Patenting Manager, Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, MD 

20852–3804; Telephone: (301) 435– 

4074; Facsimile: (301) 402–0220; E-mail: 

sstand@od.nih.gov. 

SUPPLEMENTARY INFORMATION: Adenosine 

a3 antagonists applied topically to the 

cornea have been shown to cause a 

reduction in intraocular pressure, which 

is a means of treating glaucoma. 

The invention relates to several 

structurally different pharmacophores 

that have been shown to antagonize 

adenosine a3 receptors. Molecules are to 

be tested to optimize for the treatment 

of glaucoma and intraocular pressure in 

humans. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR part 404.7. The 

prospective exclusive license may be 

granted unless within thirty (30) days 

from the date of this published notice, 

the NIH receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR part 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: February 16, 2010. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2010–3907 Filed 2–25–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–3224–N] 

Medicare Program; Request for 

Nominations for Members for the 

Medicare Evidence Development & 

Coverage Advisory Committee 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: Notice. 

SUMMARY: This notice announces the 

request for nominations for 

consideration for membership on the 

Medicare Evidence Development & 

Coverage Advisory Committee 

(MEDCAC). Among other things, the 

MEDCAC advises the Secretary of the 

Department of Health and Human 

Services (the Secretary) and the 

Administrator of the Centers for 

Medicare & Medicaid Services, as 

requested by the Secretary, whether 

medical items and services are 

‘‘reasonable and necessary’’ and 

therefore eligible for coverage under 

Title XVIII of the Social Security Act. 

We are requesting nominations for 

both voting and nonvoting members to 

serve on the MEDCAC. Nominees are 

selected based upon their individual 

qualifications and not as representatives 

of professional associations or societies. 

We have a special interest in ensuring 

that the interests of both women and 

men, members of all racial and ethnic 

groups, and physically challenged 

individuals are adequately represented 

on the MEDCAC. Therefore, we 

encourage nominations of qualified 

candidates who can represent these 

interests. 

The MEDCAC reviews and evaluates 

medical literature, reviews technology 

assessments, and examines data and 

information on the effectiveness and 

appropriateness of medical items and 

services that are covered or eligible for 

coverage under Medicare. 

DATES: Nominations will be considered 

if postmarked by Monday, March 29, 

2010 and mailed to the address 

specified in the ADDRESSES section of 

this notice. 

ADDRESSES: You may mail nominations 

for membership to the following: 

Centers for Medicare & Medicaid 

Services, Office of Clinical Standards 

and Quality, Attention: Maria Ellis, 7500 

Security Boulevard, Mail Stop: C1–09– 

06, Baltimore, MD 21244–1850. 

FOR FURTHER INFORMATION CONTACT: 

Maria Ellis, Executive Secretary for 

MEDCAC, Centers for Medicare & 

Medicaid Services, Office of Clinical 

Standards and Quality, Coverage and 

Analysis Group, C1–09–06, 7500 

Security Boulevard, Baltimore, MD 

21244 or contact Ms. Ellis by phone 

(410–786–0309) or via e-mail at 

Maria.Ellis@cms.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

On December 14, 1998, we published 

a notice in the Federal Register (63 FR 

68780) announcing establishment of the 

Medicare Coverage Advisory Committee 

(MCAC). The Secretary signed the initial 

charter for the Medicare Coverage 

Advisory Committee on November 24, 

1998. On January 26, 2007 the Secretary 

published a notice in the Federal 

Register (72 FR 3853), changing the 

Committee’s name to the Medicare 

Evidence Development and Coverage 

Advisory Committee (MEDCAC). The 

charter for the committee was renewed 

by the Secretary and will terminate on 

November 24, 2010, unless renewed 

again by the Secretary. 

The MEDCAC is governed by 

provisions of the Federal Advisory 

Committee Act, Public Law 92–463, as 

amended (5 U.S.C. App. 2), which sets 

forth standards for the formulation and 

use of advisory committees, and is 

authorized by section 222 of the Public 

Health Service Act as amended (42 

U.S.C. 217A). 

The MEDCAC consists of a pool of 

100 appointed members including: 6 

patient advocates, who are standard 

voting members; and 6 representatives 

of industry interests, who are nonvoting 

members. Members are selected from 

among authorities in clinical medicine 

of all specialties, administrative 

medicine, public health, biologic and 

physical sciences, health care data and 

information management and analysis, 

patient advocacy, the economics of 

health care, medical ethics, and other 

related professions such as 

epidemiology and biostatistics, and 

methodology of trial design. 

The MEDCAC functions on a 

committee basis. The committee reviews 

and evaluates medical literature, 

reviews technology assessments, and 


sroberts on DSKD5P82C1PROD with NOTICES